These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8986319)

  • 1. Risperidone: once-daily dosage.
    Gupta S; Droney T
    Ann Clin Psychiatry; 1996 Dec; 8(4):221. PubMed ID: 8986319
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommended haloperidol and risperidone doses in first-episode psychosis.
    McGorry PD
    J Clin Psychiatry; 1999 Nov; 60(11):794-5. PubMed ID: 10584773
    [No Abstract]   [Full Text] [Related]  

  • 3. Hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in Japan.
    Yoshimura B; Shinkawa I; Konishi A
    Asian J Psychiatr; 2015 Apr; 14():67-8. PubMed ID: 25736075
    [No Abstract]   [Full Text] [Related]  

  • 4. Risperidone: a once-daily dosage schedule.
    Gupta S; Gilroy WR
    Ann Clin Psychiatry; 1995 Dec; 7(4):211. PubMed ID: 8721896
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
    Lasser RA; Bossie CA; Gharabawi GM; Baldessarini RJ
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):427-38. PubMed ID: 15804371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching between clozapine and risperidone treatment.
    Gardner DM; Baldessarini RJ; Benzo J; Zarate CA; Tohen M
    Can J Psychiatry; 1997 May; 42(4):430-1. PubMed ID: 9161773
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction of mania by risperidone resistant to mood stabilizers.
    Barkin JS; Pais VM; Gaffney MF
    J Clin Psychopharmacol; 1997 Feb; 17(1):57-8. PubMed ID: 9004061
    [No Abstract]   [Full Text] [Related]  

  • 11. Choice of and decreasing of the dosage of risperidone in the treatment of schizophrenia. Global versus individual criteria.
    Gómez-Perretta C
    Actas Esp Psiquiatr; 2007; 35(1):77-8. PubMed ID: 17323229
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
    Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
    Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System.
    Fuller M; Shermock K; Russo P; Secic M; Dirani R; Vallow S; Flanders S
    J Med Econ; 2009; 12(4):317-24. PubMed ID: 19817665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder.
    Chue P; Welch R; Binder C
    Can J Psychiatry; 2004 Oct; 49(10):701-3. PubMed ID: 15560318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone for adolescent schizophrenia.
    Jainer AK; Mahmood A
    Br J Psychiatry; 2009 Jun; 194(6):568-9; author reply 569. PubMed ID: 19478315
    [No Abstract]   [Full Text] [Related]  

  • 17. A report of successful treatment of psychosis in epilepsy with risperidone.
    Mahgoub NA
    J Neuropsychiatry Clin Neurosci; 2007; 19(3):347-8. PubMed ID: 17827431
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
    Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
    Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
    Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S
    J Clin Psychopharmacol; 2017 Jun; 37(3):296-301. PubMed ID: 28306616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.